International Journal of Radiation Oncology*Biology*Physics
Physics contributionIntensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma
Introduction
Malignant pleural mesothelioma (MPM) is an aggressive malignancy in which local disease progression is the main cause of symptoms and death. Disseminated disease is seen only very late in the course of MPM 1, 2. MPM spreads by direct extension and seeding throughout the pleural space, including fissures, diaphragmatic and pericardial surfaces, through the chest wall, and into the mediastinum, peritoneum, and lymph nodes. The major problem for patients with MPM is poor local disease control in the thorax. Aggressive surgery alone, even in carefully selected patients, does not improve the 2-year survival rate of 10% to 33% 3, 4, 5. Although combined modality treatment has been reported to improve local control and survival rate 6, 7, 8, local recurrence is still the most common site of first relapse (9).
Even after extrapleural pneumonectomy (EPP), the diffuse nature of most malignant mesotheliomas and the manipulation of the exposed tumor during surgery puts the entire ipsilateral chest wall, diaphragm insertion, pericardium, mediastinum, and bronchial stump at very high risk of local recurrence. The hemithorax and mediastinum have an irregular shape and are adjacent to critical structures such as the spinal cord, liver, kidneys, esophagus, heart, and contralateral lung. Conventional radiotherapy to the hemithorax and mediastinum is limited by the ability of these organs to tolerate radiation 1, 9, 10 as well as by the total volume of tissue being irradiated.
Intensity-modulated radiation therapy (IMRT), however, has the potential to conform radiation doses tightly to target volumes. IMRT can reduce normal tissue toxicity, such as the parotid gland in head-and-neck neoplasms (11) and the rectum in prostate cancer (12), compared with standard techniques. In other disease sites with complex target volumes, IMRT generally results in superior dose distributions compared with those resulting from more traditional techniques.
In this study, we sought to determine whether IMRT after EPP might provide better target coverage than would traditional radiotherapeutic approaches. Because the definition of the target volume in postoperative radiotherapy of MPM has not been well described in the literature, techniques were also developed in close collaboration with thoracic surgeons to improve postoperative target definition. It was found that IMRT could be used to deliver 50 to 60 Gy to the hemithorax after EPP and that better than expected local disease control was thereby achieved. This is the initial experience with IMRT at The University of Texas M. D. Anderson Cancer Center. We here report the target volumes, dose distribution, toxicity effects, and patterns of time to disease recurrence and length of survival.
Section snippets
Patient data
Between June 2000 and February 2001, 7 patients with MPM underwent EPP. After giving informed consent, they were treated with adjuvant IMRT. Patient characteristics are shown in Table 1. All patients were men, though this was not part of the selection criteria. Their disease was staged using the two most common mesothelioma classification systems 13, 14, 15.
Patient selection, staging, and follow-up
Thoracic surgeons at M. D. Anderson Cancer Center identified potential candidates for the study. Eligible patients must have undergone EPP
Surgical findings
The features of the tumors found at surgery and upon pathologic examination are shown in Table 3. All of the tumors were quite extensive and often involved the chest wall or lung at multiple locations. Four of the 7 patients were found to have disease involving the lymph nodes.
Treatment planning and setup
In this group of patients, radiotherapy treatment planning required 3 to 8 weeks from the time of simulation to the first treatment. One patient required replanning because of an unavoidable 8-week delay from simulation
Discussion
The incidence of MPM in the United States is rising 17, 18, and is likely to continue to increase due to the 35- to 40-year lag between asbestos exposure and clinical presentation of the MPM 19, 20, 21. Other carcinogens such as the simian virus-40 also may play a role in MPM 22, 23, suggesting that the peak incidence of MPM may be many years away.
The prognosis for MPM has traditionally been dismal; the median length of survival is 4 to 12 months without intervention 24, 25, 26. In a
Conclusions
IMRT after EPP for MPM is feasible, and greatly facilitated by close interaction between the thoracic surgeon, radiation oncologist, and radiation physicist. Toxicity is modest, with the most serious side effects being fatigue and anorexia. Local control is excellent, with promising survival results at this early time.
References (38)
Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma
Chest
(1993)- et al.
Radiation therapy in the management of patients with mesothelioma
Int J Radiat Oncol Biol Phys
(1982) - et al.
The role of extrapleural pneumonectomy in malignant pleural mesotheliomaA Lung Cancer Study Group trial
J Thorac Cardiovasc Surg
(1991) - et al.
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesotheliomaResults in 183 patients
J Thorac Cardiovasc Surg
(1999) - et al.
Computerized tomography scanning and the planning of high dose radiotherapy for pleural mesotheliomaA report of five patients
Int J Radiat Oncol Biol Phys
(1981) - et al.
Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer
Int J Radiat Oncol Biol Phys
(1999) - et al.
Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer
Radiother Oncol
(2000) A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group
Lung Cancer
(1996)- et al.
Benign and malignant pleural mesothelioma
Clin Chest Med
(1985) - et al.
Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences
J Thorac Cardiovasc Surg
(1998)
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically
Ann Thorac Surg
Operation and intracavitary photodynamic therapy for malignant pleural mesotheliomaA phase II study
Ann Thorac Surg
Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma
Int J Radiat Oncol Biol Phys
Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma
Int J Radiat Oncol Biol Phys
Radiation therapy in the management of patients with mesothelioma
Int J Radiat Oncol Biol Phys
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleuraExperience with 29 patients
Thorax
Treatment of malignant mesothelioma
World J Surg
Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital
Anticancer Res
Malignant mesothelioma of the pleuraA prospective therapeutic study of 132 patients from 1981–1985
Klinische Wochenschrift
Cited by (128)
Return to intended oncologic treatment after surgery for malignant pleural mesothelioma
2019, Journal of Thoracic and Cardiovascular SurgeryRadiotherapy for the treatment of malignant pleural mesothelioma
2017, The Lancet OncologyCitation Excerpt :Overall, the percentage of patients who developed pneumonitis was 13%.40 Multiple groups34,38,40–44 have since confirmed that high-dose hemithoracic IMRT can be safely delivered with percentages of grade 3 or 4 pneumonitis of less than 14% and of grade 5 (fatal) toxicity of less than 6% when strict constraints are applied to the contralateral lung (table 2). Other studies43,66 have also confirmed the use of high-dose hemithoracic IMRT to improve local control compared with 3DCRT in patients with malignant pleural mesothelioma.
Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma
2015, Journal of Thoracic and Cardiovascular SurgeryAdvances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies
2015, Critical Reviews in Oncology/HematologyUncommon Thoracic Tumors
2015, Clinical Radiation Oncology